Project: A novel diagnostic assay to stratify lung cancer patients with EGFR therapy resistance.

A deletion in the proto-oncogene MET (delta78MET) causes MET activation and resistance to EGFR inhibitors which presents a major clinical problem. DELTAMET will validate delta78MET as a novel predictive biomarker and delivers a novel diagnostic assay which accurately predicts resistance to EGFR inhibitors in advanced lung cancer patients with aberrant MET activation and the first companion diagnostic assay able to stratify patients responsive to MET inhibitors for personalised medicine.

Acronym DELTAMET (Reference Number: 9616)
Duration 01/10/2015 - 01/10/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 3

Project partner

Number Name Role Country
21084 thromboDx Coordinator Netherlands
21085 Radboud UMC Partner Netherlands
21086 Pangaea Biotech Partner Spain